GLP1R and type 2 diabetes mellitus: This cohort study comprising 27 279 participants with type 2 diabetes and advanced-stage chronic kidney disease or end-stage kidney disease revealed that the use of GLP-1 receptor agonists was associated with lower all-cause mortality and lower sepsis- and infection-related mortality than was use of DPP-4 inhibitors.